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Background. Overproduction of transforming growth factor-b
(TGF-b) is a key mediator of extracellular matrix accumulation in
fibrotic diseases. We hypothesized that the degree of reduction of
pathological TGF-b expression can be used as a novel index of the
antifibrotic potential of angiotensin II (Ang II) blockade in renal
disease.
Methods. One day after induction of Thy 1.1 glomerulonephri-
tis, rats were treated with increasing doses of the Ang I converting
enzyme (ACE) inhibitor enalapril and/or the Ang II receptor
blocker losartan in the drinking water. Six days after disease
induction the therapeutic effect on glomerular TGF-b overexpres-
sion was evaluated.
Results. Both enalapril and losartan reduced TGF-b overpro-
duction in a dose-dependent manner, showing a moderate reduc-
tion at doses known to control blood pressure in renal forms of
hypertension. A maximal reduction in TGF-b expression of
approximately 45% was seen for both drugs starting at 100
mg/liter enalapril and 500 mg/liter losartan, with no further
reduction at doses of enalapril up to 1000 mg/liter or losartan up
to 2500 mg/liter. Co-treatment with both drugs was not superior to
single therapy. Consistent with our hypothesis that reduction in
TGF-b expression is a valid target, other disease measures,
including glomerular matrix accumulation, glomerular production
and mRNA expression of the matrix protein fibronectin and the
protease inhibitor plasminogen-activator-inhibitor type 1 (PAI-1)
closely followed TGF-b expression.
Conclusions. The data suggest that these therapies act through
very similar pathways and that, in order to more effectively treat
renal fibrosis, these drugs must be combined with other drugs that
act by different mechanisms.
Progressive accumulation of extracellular matrix is a
main cause of chronic renal disease in both animals and
humans [1]. Fibrosis of the glomerulus and the tubuloint-
erstitium impairs the kidney function and finally leads to
organ failure. Over the last years considerable evidence has
accumulated showing that overproduction of the cytokine
transforming growth factor-b (TGF-b) plays a key role in
renal fibrosis [1]. In particular, a number of very different
factors known to be injurious to the kidney have been
shown to significantly increase TGF-b expression. These
factors include angiotensin II (Ang II), hypoxia, high
glucose levels, autoantibodies, immune complexes, ad-
vanced glycosylation end products, mesangial cell stretch
and platelet derived growth factor (PDGF), TGF-b and
basic fibroblast growth factor (bFGF) [reviewed in 2, 3].
Overproduction of TGF-b in turn strongly induces and
orchestrates an array of events leading to matrix accumu-
lation and tissue fibrosis. These events include: (1) in-
creased synthesis of matrix proteins such as collagens,
fibronectin and proteoglycans; (2) decreased degradation
of matrix proteins by suppression of protease expression
and increased production of protease inhibitors such as
plasminogen-activator-inhibitor type 1 (PAI-1) or TIMP;
and (3) increased synthesis and expression of a group of
cell-matrix receptors called integrins which enhance local
matrix deposition [1].
In rats with anti-thymocyte-serum (ATS)-induced glo-
merulonephritis, we have previously shown that treatment
with TGF-b neutralizing antibodies or the natural TGF-b
antagonist decorin greatly reduces pathological glomerular
matrix expansion, suggesting a causative role for TGF-b in
renal fibrosis [4–6]. This notion has recently been con-
firmed using gene transfer techniques. Isaka et al have
demonstrated that introduction of the functional TGF-b1
gene into normal glomeruli markedly increases production
of extracellular matrix proteins and rapidly leads to glomer-
ulosclerosis [7]. Furthermore, Kopp et al have reported
that transgenic mice with high circulating TGF-b1 develop
severe progressive kidney fibrosis and die from renal failure
[8].
Drugs that block the actions of Ang II have shown
beneficial effects in a number experimental kidney diseases
[2]. ACE inhibitors and the newly available class of Ang II
receptor type 1 antagonists effectively lessen proteinuria,
reduce systemic and glomerular hypertension and prevent
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development of kidney fibrosis. In humans with diabetic or
IgA nephropathy, ACE inhibition slows the progressive loss
of renal function and delays the requirement for dialysis or
transplantation [reviewed in 2, 9]. Several recent experi-
mental studies have demonstrated that Ang II blockade
results in a decrease in TGF-b expression and matrix
accumulation, suggesting that the antifibrotic effect is me-
diated through a reduction of this fibrogenic cytokine
[reviewed in 2, 3]. None of these studies specifically asked
how much reduction in TGF-b is possible with these drugs.
Although systemic or glomerular hypertension is an
important factor in renal injury, several lines of evidence
suggest that the therapeutic effect of Ang II blockade is
partially independent of the hemodynamic effects. For
instance, in rats with deoxycorticosterone acetate salt hy-
pertension, ACE inhibitors and Ang II receptor blockers
effectively limit renal fibrosis with no effect on systemic
blood pressure [10]. In addition, ACE inhibitors signifi-
cantly slow the progression of renal failure in patients even
in the absence of increased blood pressure [11]. Neverthe-
less, the doses of ACE inhibitors or Ang II receptor
blockers used are based on their effects on systemic blood
pressure and preservation of filtration rather than by their
antifibrotic effect.
Since overexpression of TGF-b has a central role in renal
fibrosis, we asked whether the efficacy of Ang II blockade
on matrix accumulation could be maximized if reduction in
TGF-b overexpression is the target. For this study we used
the anti-thymocyte model of acute mesangioproliferative
glomerulonephritis. There are several reasons for using this
model. First, we have spent much time evaluating different
markers of disease and different sacrifice times with the
goal of using those giving a large difference between
normal and disease control groups, thereby maximizing the
window available for detecting small differences in thera-
peutic efficacy. Second, although glomerular hypertension
is present for a short period early [12], this model is not
considered a hypertensive model. Efficacy of angiotensin II
blockade would therefore be expected to be due to other
pathways by which Ang II acts on disease. Finally, we have
undertaken a series of studies aimed at systematically
comparing currently available and promising treatments for
renal fibrosis with emphasis on the question of what is the
maximum effect possible with one drug and whether com-
bined therapy enhances disease reduction.
In the present study, we addressed the following ques-
tions: (1) At what doses are the antifibrotic effects of the
ACE inhibitor enalapril or of the Ang II receptor antago-
nist losartan maximal? (2) Are enalapril and losartan
equipotent at these doses? (3) Will inhibition of Ang II
generation and blockade of Ang II type 1 receptors to-
gether be more effective than single treatment at maximally
effective doses? Compared to other models of renal dis-
ease, the experimental model used in this study is charac-
terized by a very rapid and marked glomerular TGF-b
overexpression and accumulation of extracellular matrix.
Using new methods to detect production of TGF-b and
disease markers fibronectin and PAI-1 in the supernatant
of cultured nephritic glomeruli, this model is highly sensi-
tive to small differences in therapeutic efficacy.
METHODS
Materials
If not otherwise indicated, materials, chemicals or cul-
ture media were purchased from Sigma Chemical Co. (St.
Louis, MO, USA).
Animals
The studies were performed in male Sprague Dawley
(SD) rats (200 to 270 g) obtained from Sasco (Omaha, NE,
USA). Animal housing and care were in accordance with
the NIH Guide for the Care and Use of Laboratory Animals,
NIH Publication No. 85-23, 1985. Animals were fed a
normal protein diet (22% protein, Teklad No. 86 550;
Teklad Premier Laboratory Diets, Madison, WI, USA).
Glomerulonephritis was induced by tail vein injection of
the monoclonal anti-Thy 1.1 antibody OX-7 (1.5 mg/1 kg).
OX-7 binds to a Thy 1.1-like epitope on the surface of
mesangial cells and causes complement-dependent cell lysis
[13]. Control animals were injected with the similar vol-
umes of phosphate buffered saline (PBS). Body weight and
food intake was monitored at the beginning and end of
each experiment.
OX-7 production
The monoclonal antibody was produced in the ascitic
fluid of adult female BALB/c mice (Charles River, Wil-
mington, MA, USA). The hybridoma was obtained from
American Type Culture Collection (Rockville, MD, USA)
and grown in RPMI 1640 (Gibco BRL, Long Island, NY,
USA) supplemented with 10% FCS, 100 U/ml penicillin,
100 mg/ml streptomycin and 25 mM HEPES buffer at
37°C/5% CO2. Cells were passaged at confluence. The mice
were primed with two intraperitoneal injections of 0.5 ml
pristane (2,6,10,14-tetramethyldecanoic acid) one week
apart. Three days after the second pristane administration,
the hybridoma cells were spun at 3000 g for five minutes
and resuspended in PBS (pH 7.4). Approximately 1 to 2
million cells in 0.5 ml PBS were injected intraperitoneally
into each mouse. When mice had developed noticeable
ascites, they were anesthetized with ether and the ascitic
fluid was collected.
To purify the IgG fraction, ascitic fluid was combined
with 2/10 volumes 1.0 M Tris buffer (pH 8.0) and applied to
a pre-equilibrated Protein G column (Pierce, Rockford, IL,
USA). The antibody fraction was eluted with 100 mM
glycine (pH 3.0) and promptly neutralized with Tris buffer
(pH 9.0). After extensive dialysis against PBS (pH 7.4), the
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antibody concentration was adjusted to 1 mg/ml by reading
the adsorbance at 280 nm and stored at 270°C until use.
Angiotensin II blockade
The ACE inhibitor enalapril maleate and the Ang II
receptor type 1 antagonist losartan were used. Losartan was
kindly provided by DuPont Merck Pharmaceuticals Co.
(Wilmington, DE, USA). Enalapril maleate is a prodrug
and is converted in the liver to form the active metabolite
enalaprilate [14]. In rats and humans, losartan is itself
active but is also converted to the several-fold more active
metabolite, EXP3174 [15]. Both enalapril and losartan
show a relatively long lasting effect on blood pressure
allowing single dosing per day [14, 15]. Doses comparable
to a drug intake achieved with 20 to 50 mg/liter enalapril or
50 to 100 mg/liter losartan given in the drinking water have
been shown to sufficiently control blood pressure in models
of renal hypertension, including the remnant kidney and
Goldblatt models [14–17].
Experimental design
Experiment 1. Effect of increasing doses of enalapril in the
drinking water on glomerular TGF-b1 production six days
after disease induction. Sprague Dawley rats were assigned
to the following groups: (1) PBS-injected controls (N 5 4),
(2) OX-7-injected rats drinking tap water only (N 5 4), and
(3) OX-7-injected rats drinking water with 10, 20, 50, 100,
200, 500 and 1000 mg/liter enalapril (N 5 3 each).
Experiment 2. Effect of increasing doses of losartan in the
drinking water on glomerular TGF-b1 production six days
after disease induction. In this experiment, rats were as-
signed to the following groups: (1) PBS-injected controls
(N 5 4), (2) OX-7-injected rats drinking tap water only
(N 5 4), and (3) OX-7-injected rats drinking water with 50,
100, 250, 500, 1000 and 2500 mg/liter losartan (N 5 3 each).
Experiment 3. Combined effect of maximally effective doses
of enalapril and losartan on glomerular TGF-b1 production
six days after disease induction. Based on results from
experiments 1 and 2, the minimum doses of enalapril (100
mg/liter) and losartan (500 mg/liter), which maximally
reduced TGF-b overexpression, were used. Rats were
assigned to the following groups: (1) PBS-injected controls
(N 5 4), (2) OX-7-injected rats drinking tap water only
(N 5 4), (3) OX-7-injected rats with 100 mg/liter enalapril
(N 5 4), (4) OX-7-injected rats with 500 mg/liter losartan
(N 5 3), and (5) OX-7 injected rats drinking water with 100
mg/liter enalapril and 500 mg/liter losartan (N 5 4).
In all three experiments, drug treatment was started 24
hours after disease induction. At that time, based on an
average water intake of 40 ml per day, 60% of the daily
dose was administered by gavage. Thereafter, the animals
were housed in metabolic cages to monitor the water and
drug intake individually. The amount of drug in the drink-
ing water was adjusted daily to that amount each animal
would receive by drinking 40 ml water. Systolic blood
pressure was measured in the conscious state by tail cuff
method as previously described the day before the end of
the experiment [18].
Six days after induction of glomerulonephritis, the ani-
mals were anesthetized with ether. Following a midline
abdominal incision, 5 to 10 ml blood was drawn from the
lower abdominal aorta and the kidneys were subsequently
perfused with 30 ml ice-cold PBS. For histological exami-
nation cortical tissue was snap frozen and fixed in 10%
neutral buffered formalin. Glomeruli from individual rats
were isolated by a graded sieving technique (150, 125, 106
and 75 mm mesh metal sieves) as described previously [19]
and resuspended at 2000 glomeruli/ml/well in DMEM
supplemented with 0.1 U/ml insulin, 100 U/ml penicillin,
100 mg/ml streptomycin and 25 mM HEPES buffer. After a
72 hours incubation at 37°C/5% CO2, the supernatant was
harvested and stored at 270°C until analysis of glomerular
production of TGF-b1, fibronectin and PAI-1.
Measurement of TGF-b1, fibronectin and PAI-1
TGF-b1 production of cultured glomeruli was measured
after acid activation using a commercially available inhibi-
tory enzyme-linked immunosorbant assay (ELISA) kit
(Quantikiney, R&D Systems, Minneapolis, MN, USA)
according to the manufacturer’s instructions. Therefore,
this method only measured total TGF-b1. Fibronectin and
PAI-1 synthesis were measured with modified ELISA as-
says according to published methods [20]. Three samples
from each rat were analyzed.
Light microscopy
All microscopic examinations were performed in a
blinded fashion. Three micrometer sections of paraffin-
embedded tissue were stained with periodic acid-Schiff
(PAS) and glomerular matrix expansion was evaluated as
previously described [19]. Briefly, in 30 glomeruli from each
rat the percentage of mesangial matrix occupying each
glomerulus was rated as: 0 5 0%, 1 5 25%, 2 5 50%, 3 5
75% and 4 5 100%.
RNA preparation and Northern hybridization
Total RNA was extracted by a guanidinium isothiocyante
method using Trizol® reagent according to the manufac-
turers instructions. Isolated glomeruli from three to four
rats from the experimental group 3 were pooled for subse-
quent RNA extraction. For Northern analysis, RNA was
denatured and fractionated by electrophoresis through a
1.8% agarose gel (30 mg/lane) and transferred to a Hybond
nylon membrane (Amersham Corp., UK). Nuclei acids
were immobilized by UV irradiation. Membranes were
prehybridized with 50% formamide, 10% Denhardt’s solu-
tion, 0.1% SDS, 5 3 SSC and 200 mg/ml denatured salmon
sperm DNA and hybridized with DNA probes labeled with
32P-dCTP by random oligonucleotide priming (Boehringer
Mannheim Biochemicals, Indianapolis, IN, USA). The
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blots were washed in 2 3 SSC, 0.1% SDS at room
temperature for 15 minutes and in 0.1 3 SSC, 0.1% SDS at
55°C for 30 minutes. DNA probes used were: (1) rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA (a gift form Drs. P. Kondaiah and M.B. Sporn) [21],
(2) TGF-b1 cDNA (kindly provided from Dr. D.L. Moses)
[22], (3) fibronectin-EDA cDNA (a generous gift from Dr.
R.O. Hynes) [23], and (4) PAI-1 cDNA (kindly provided by
Dr. T.D. Gelehrter) [24]. Three blots per probe were
performed.
Statistical analysis
Data are expressed as mean 6 SEM. Statistical analysis of
differences between the groups was performed by ANOVA
and subsequent t-testing with Bonferroni correction for
multiple comparison. Comparisons with a P value , 0.05
were considered significantly different.
RESULTS
Body weight, food consumption, drinking volume
There were no significant differences in body weight,
food intake and drinking volume between the groups
investigated. All animals drank more than 20 ml per day.
In all three experiments, measures of disease severity
were very similar (Figs. 1 to 3). Compared to the normal
control group, the mean TGF-b1 production of cultured
nephritic glomeruli from untreated animals was increased
8.7-fold, and glomerular production of fibronectin and
PAI-1 synthesis were increased by 7.4-fold and 16.6-fold,
Fig. 1. Effect of increasing doses the ACE inhibitor enalapril in the drinking water on: (A) glomerular matrix accumulation, (B) glomerular TGF-b1
production, (C) glomerular fibronectin production, and (D) glomerular PAI-1 production. In male Sprague Dawley rats treatment was started one day
after injection of OX-7 (GN). The kidneys were harvested six days after disease induction.
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respectively. The mean glomerular matrix score increased
from 1.39 in the normal animals to 2.45 in the disease
controls.
Systolic blood pressure in the PBS-injected controls was
114 6 11 mm Hg in experiment 1, 109 6 9 mm Hg in
experiment 2 and 108 6 12 mm Hg in experiment 3. In the
disease controls drinking tap water only, blood pressure
was 111 6 11, 118 6 14 and 117 6 15 mm Hg, respectively.
Treatment with enalapril, losartan or both together did not
significantly change systolic blood pressure.
Experiment 1
As shown in Figure 1B, treatment with enalapril in the
drinking water reduced glomerular TGF-b1 production in a
dose-dependent manner. A moderate decrease in patho-
logical TGF-b1 production of approximately 20 to 25% was
seen in rats treated with 10 to 20 mg enalapril/liter drinking
water (Fig. 1). With increasing doses of enalapril, a maxi-
mal reduction of approximately 45% in TGF-b1 production
was seen starting in animals treated with 100 mg enalapril.
A further increase in the enalapril dose did not further
decrease glomerular TGF-b1 production (200 mg: 41%;
500 mg: 45%; 1000 mg: 45%). The accumulation of extra-
cellular matrix in the glomeruli following OX-7 injection
showed a similar pattern (Fig. 1A). Compared to the
disease control group (2.56 6 0.04) lower doses of enalapril
(10, 20 and 50 mg/liter) reduced the matrix score slightly to
2.28 6 0.04, 2.12 6 0.12 and 2.16 6 0.20, respectively.
Higher doses of enalapril (100, 200, 500 and 1000 mg/liter)
prevented glomerular matrix accumulation more effectively
giving matrix scores of 1.92 6 0.20, 2.00 6 0.20, 2.04 6 0.08
and 2.00 6 0.04, respectively.
Since TGF-b1 is a potent stimulator of fibronectin and
PAI-1 synthesis, we used their production by isolated
glomeruli as an additional indicator of therapeutic efficacy
of Ang II blockade on TGF-b1 expression in our system.
Similar to the glomerular TGF-b production and matrix
accumulation, treatment of nephritic animals with increas-
ing doses of enalapril reduced glomerular fibronectin and
PAI-1 production in a dose-dependent manner. Glomeruli
isolated from the disease control animals produced 4953 6
729 ng/ml fibronectin and 185 6 19 ng/ml PAI-1 (Fig. 1, B
and C, respectively). Treatment with 10, 20, 50, 100, 200,
500 and 1000 mg enalapril in the drinking water decreased
the glomerular fibronectin by 13%, 24%, 40%, 46%, 36%,
40% and 42%, respectively. The glomerular PAI-1 produc-
tion was decreased by 36%, 35%, 64%, 59%, 66%, 58% and
64%, respectively.
Experiment 2
Similar to enalapril in experiment 1, treatment of ne-
phritic rats with increasing doses of losartan decreased
glomerular TGF-b1 overproduction in a dose-dependent
manner as well. Addition of 50 mg or 100 mg losartan to the
drinking water reduced pathological glomerular TGF-b1
production only by 20 to 25% (Fig. 2B). Higher doses of
losartan decreased the TGF-b1 production more effec-
tively. A maximal decrease of approximately 45% was seen
at 500 mg/liter losartan, however, a further increase in the
losartan dose did not further decrease TGF-b1 production
(1000 mg, 38%; 2500 mg, 40%). Compared to the matrix
accumulation seen in the disease controls (2.40 6 0.04),
treatment of nephritic rats with 50, 100, 250, 500, 1000 and
2500 mg losartan decreased the matrix score to 2.24 6 0.08,
2.20 6 0.12, 2.00 6 0.08, 1.84 6 0.04, 1.88 6 0.16 and
1.84 6 0.04, respectively (Fig. 2A). Glomerular fibronectin
and PAI-1 production were decreased dose-dependently as
well (Fig. 2 B, C). Treatment of nephritic rats with increas-
ing doses of losartan reduced glomerular fibronectin pro-
duction by 21%, 14%, 28%, 41%, 49% and 36%, respec-
tively. The glomerular PAI-1 production decreased by 29%,
37%, 58%, 61%, 54% and 62%, respectively.
Experiment 3
The minimum doses of enalapril and losartan showing
maximal TGF-b1 reduction were combined to look for
additive effects of these drugs on disease severity. From
experiments 1 and 2, the doses of 100 mg/liter enalapril and
500 mg/liter losartan (Figs. 1 and 2), were chosen. The
results clearly show that, at these doses, a combination of
enalapril and losartan was not superior to one form of Ang
II blockade alone (Fig. 3). Treatment of rats with 100
mg/liter enalapril in the drinking water reduced glomerular
TGF-b1 synthesis by 41%, therapy with 500 mg/liter losar-
tan by 45% and treatment with both 100 mg/liter enalapril
and 500 mg/liter losartan by 45% reduction (Fig. 3B).
Compared to the disease control animals, glomerular ma-
trix accumulation was also equally reduced in the three
treatment groups (Fig. 3A; matrix score of 2.40 6 0.04 vs.
1.84 6 0.04, 1.84 6 0.12 and 1.80 6 0.04, respectively). The
glomerular production of fibronectin and PAI-1 showed a
similar picture (Fig. 3 C, D). Treatment of nephritic rats
with enalapril or losartan or both decreased the glomerular
fibronectin by 41%, 37% and 41%, respectively. The glo-
merular synthesis of PAI-1 decreased by 52%, 61% and
56%, respectively.
In experiment 3, the glomerular mRNA expression of
TGF-b1, fibronectin and PAI-1 in addition to their glomer-
ular protein production was analyzed (Fig. 4). Reduction of
these mRNAs were not as great as the decrease in their
protein production. Again, as shown in Figure 4, treatment
of nephritic rats with maximally effective doses of enalapril
or losartan or both decreased the glomerular TGF-b1,
fibronectin, and PAI-1 mRNA levels significantly (P ,
0.05), and to a similar extent (P . 0.05). Compared to the
disease control animals, treatment with 100 mg/liter enala-
pril or 500 mg/liter losartan or both reduced glomerular
TGF-b1 mRNA expression by 16%, 16% and 21%, respec-
tively. Glomerular fibronectin mRNA levels were de-
creased by 26%, 30% and 22% and glomerular PAI-1
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mRNA expression were decreased by 25%, 25% and 25%,
respectively.
DISCUSSION
Fibrotic diseases are characterized by the accumulation
of extracellular matrix. The current state of our knowledge
suggests that TGF-b overexpression is responsible for this
accumulation through its actions to induce production of
extracellular matrix, inhibit its degradation and increase
integrin expression on cells, thereby enhancing matrix
deposition. TGF-b overexpression may be viewed as the
final common element in fibrotic diseases [1]. A large
number of stimuli induce its expression. Of relevance to
renal disease are Ang II, cell damage or lysis, immune
complex deposition, high glucose, advanced glycosylated
end products, shear stress and mesangial stretch as well as
exogenously delivered cytokines TGF-b, PDGF and bFGF
[reviewed in 3]. It is noteworthy that most models of renal
disease, as well as most human renal diseases, involve
increases in one or more of these stimuli.
Evidence is mounting rapidly that reduction of TGF-b
overexpression in models of fibrosis decreases pathological
matrix accumulation, whether the therapy is neutralizing
antibodies to TGF-b, decorin, low protein intake, angio-
tensin II blockade or L-arginine supplementation [2, 4–6,
18, 25, 26]. Very recently, two human studies reported in
abstract form that angiotensin blockade is associated with
reduction in TGF-b overexpression. The first showed a
reduction in glomerular TGF-b mRNA expression in IgA
patients taking ACE inhibitors [27], and the second re-
ported reductions in plasma TGF-b levels in diabetic
patients after six months treatment with captopril [28].
Fig. 2. Effect of increasing doses of the Ang II receptor type 1 antagonist losartan in the drinking water on: (A) glomerular matrix accumulation, (B)
glomerular TGF-b1 production, (C) glomerular fibronectin production, and (D) glomerular PAI-1 production. Treatment was started one day after
injection of OX-7 (GN). The kidneys were harvested six days after disease induction.
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Since fibrotic diseases are characterized by TGF-b overex-
pression, we took a further step to quantitate TGF-b
overexpression as a marker of disease severity and to test
the hypothesis that the of degree of reduction of TGF-b is
a useful molecular marker of the therapeutic efficacy of
commonly used and new antifibrotic therapies.
The model of mesangioproliferative glomerulonephritis
used in this study is one in which administration of an
antibody to the Thy 1.1 epitope on glomerular mesangial
cells leads to immune-mediated, complement-dependent
mesangial cell lysis. Evidence supports the notion that this
model has great relevance because it contains all of the
disease elements demonstrated in human fibrotic diseases,
whether acute or chronic. Another advantage of this model
is that it is rapid, reproducible and, as clearly demonstrated
in this study, can be used to very sensitively discriminate
between therapeutic regimens. It is clear that a single
injury, whether mesangial cell lysis, or chemical damage
due to administration of aminonucleoside or adriamycin,
rarely leads to chronic disease. However, if injury in these
models is repeated, disease does often progress. Similarly
in humans, one bout of post-streptococcal glomerulone-
phritis rarely produces progressive disease. Other models
may also be progressive because the injury is repeated or
continual. For example, removal of 5/6 of the renal mass
produces persistent hypertensive injury. Similarly, ligating a
ureter to produce ureteral obstruction results in continual
hydrostatic injury. In diabetes, periodic episodes of hyper-
glycemia or repeated deposition of advanced glycosylated
endproducts may be perceived as repeated injury. It is also
possible, if injury subsided in these models, that renal tissue
might have some capacity to recover.
Fig. 3. Effect of the maximally effective doses of enalapril (Ena, 100 mg/liter) or losartan (Los, 500 mg/liter) or both (100 mg/liter enalapril and 500
mg/liter losartan) on: (A) glomerular matrix accumulation, (B) glomerular TGF-b1 production, (C) glomerular fibronectin production, and (D)
glomerular PAI-1 production. Treatment was started one day after injection of OX-7 (GN). The kidneys were harvested six days after disease induction,
*P , 0.01 versus GN.
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The two drugs used in this study are both important
antihypertensives. Studies comparing ACE inhibitors with
other drugs reducing blood pressure have long suggested
that Ang II has pressure-independent fibrogenic actions
[29]. However, only recently has Ang II been shown be
directly fibrogenic by up-regulating TGF-b, matrix protein
synthesis and PAI-1 in culture, in the absence of increased
pressure [reviewed in 3]. Angiotensin blockade with ACE
inhibitors and/or Ang II type 1 receptor antagonists has
been shown to reduce fibrosis in a large number of disease
models and in an ever-growing number of human trials
[reviewed in 30]. In a few of these studies TGF-b overex-
pression was investigated. We have previously noted that
the observed reductions in TGF-b overexpression with
angiotensin blockade were usually on the order of 40 to
60% [2]. A primary goal of the present study was to
determine whether higher does of these drugs can reduce
TGF-b overproduction and fibrosis more completely. A
secondary goal was to determine whether, when these
drugs are combined, at doses showing maximal effects
alone, any additive effects are seen.
The results demonstrate that increasing doses of enala-
pril or losartan results in a dose-dependent antifibrotic
effect. The maximal reduction in pathological glomerular
Fig. 4. Effect of maximally effective doses of enalapril (Ena, 100 mg/liter) or losartan (Los, 500 mg/liter) or both (100 mg/liter enalapril and 500
mg/liter losartan) on mRNA expression. (A) Representative Northern blot. The relative glomerular mRNA expression of TGF-b1 is depicted in (B),
fibronectin in (C), and PAI-1 in (D). Treatment was started one day after injection of OX-7 (GN). The glomerular mRNA was isolated six days after
disease induction and is expressed in relation to GAPDH expression, *P , 0.05 versus GN. Glomerular size markers are shown on the right.
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TGF-b1 overexpression and matrix accumulation was seen
at doses higher than those known to control blood pressure
in experimental forms of hypertension [15–17]. At the
lower doses of Ang II blockade, only a moderate antifi-
brotic effect was seen. This finding is consistent with a
previous report showing that, following 5/6 nephrectomy in
rats, a higher dose of ACE inhibitor reduced histological
evidence of renal fibrosis more effectively than a lower one
despite a similar effect on blood pressure [31]. The present
study expands this observation to a broader range of doses,
adds a receptor antagonist, and again shows that dosing is
very important. Two other studies have used Ang II
blockade in the ATS model. One showed a therapeutic
effect in hypertensive animals [32] and the other, very
recently published, showed data similar to that presented
here except without multiple doses or combination therapy
[33].
After a point, increasing doses did not lead to further
reduction in TGF-b expression or any other measure of
disease. It was impossible to normalize TGF-b expression.
This result is consistent with human data where Ang II
blockade slows, but does not halt the progressive loss of
renal function [reviewed in 2, 9] and strongly implies that
Ang II blockade alone cannot prevent end-stage renal
fibrosis. The data also suggest that, at least in this model of
disease, the two drugs used are almost identical in the
antifibrotic effect seen at maximal doses. To our knowledge
this is the first such side-by-side comparison of ACE
inhibition and angiotensin receptor antagonism at many
doses.
New data are beginning to appear suggesting that these
drugs have actions other than blocking Ang II that lead to
increases in beneficial, vasodilatory nitric oxide. ACE in-
hibitors block proteases other than ACE, producing an
accumulation of bradykinin and increased nitric oxide
synthesis [9]. Ang II receptor antagonists induce accumu-
lation of large amounts of Ang II and Ang II breakdown
products [34], and these breakdown products have been
reported to induce vasodilation via a kinin/nitric oxide
pathway [35, 36]. High levels of circulating Ang II cause
increased signaling through the Ang II type 2 receptor. This
may also lead to increased nitric oxide production [36, 37].
That these pathways can be important has been recently
suggested in a model of cardiac fibrosis where selective
blockade of the Ang II type 2 receptor or the bradykinin
receptor largely reversed the beneficial effect seen in
animals treated only with an Ang II receptor type 1
antagonist [38]. While the present study does not address
these questions directly, the striking equipotency of maxi-
mally effective doses of enalapril and losartan, and the
absence of any additive therapeutic effect, suggest that
there are similarities in the mechanisms of action. If indeed
enhanced nitric oxide production is an important action of
both drugs, albeit via different pathways, the data suggest
that at maximally effective doses, both drugs enhance nitric
oxide to levels that are maximally therapeutic. Otherwise
there should be some drug additivity. It remains most likely
that both of these drugs act primarily to reduce the actions
of Ang II that occur through the type 1 receptor.
It has been suggested that the simultaneous use of ACE
inhibition and Ang II receptor antagonism is required to
achieve maximal inhibition of Ang II [39, 40]. Our results
suggest that this may be true if both drugs are at sub-
maximal doses, but not if given at maximal antifibrotic
doses. However, the use of both drugs together at sub-
optimal doses might reduce the frequency of side effects
while providing maximal therapeutic efficacy.
The mechanisms of action of these drugs are clearly
complex, and some of their actions may be as yet unknown.
For example, because Ang II may stimulate mesangial cell
proliferation [41, 42], blocking its action may reduce pro-
liferation so that the number of activated mesangial cells
overproducing TGF-b, fibronectin and PAI-1 is reduced.
Thus, one could argue that the therapeutic effects shown
here result only from less mesangial cell proliferation.
However, since Ang II induces increases in TGF-b [43, 44]
and TGF-b stimulates PDGF receptor expression [45–47],
potentially making mesangial cells more sensitive to the
proliferative actions of PDGF, one could also argue that
reduced cell proliferation in response to Ang II blockade
are TGF-b mediated. It appears to us that the in vivo
situation is simply too complex to be certain which path-
ways are operating. However, the paradigm “where there is
overexpression of TGF-b there is fibrosis” is well estab-
lished and is the basis for our therapeutic targeting of
TGF-b overproduction, regardless of the complexity of the
mechanisms underlying the observed TGF-b reduction.
In summary, the present study demonstrates that quan-
titation of TGF-b overexpression can be a powerful param-
eter with which to compare and contrast different thera-
peutic approaches to fibrotic renal diseases and that the
Thy 1.1 model of glomerulonephritis is an excellent model
in which to do this. TGF-b overexpression and fibrotic
disease were reduced more effectively at doses of enalapril
and losartan that are higher than those known to reduce
blood pressure. Enalapril and losartan are equipotent at
maximally effective doses and combined therapy yields no
additional effect. Perhaps most importantly, in our efforts
to prevent renal fibrosis in humans, is this study’s strong
suggestion that neither ACE inhibition nor Ang II type
receptor antagonism will be sufficient to normalize over-
production of TGF-b. While these therapies clearly have
efficacy, it is likely that they must be combined with other
agents, which act through different mechanisms, in order to
ultimately stop disease.
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APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; Ang II, angiotensin II; ATS, anti-thymocyte serum; bFGF, basic
fibroblast growth factor; ELISA, enzyme-linked immunosorbant assay;
FCS, fetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase; IgA, immunoglobulin A; PAI-1, plasminogen activitor inhibitor type
1; PBS, phosphate buffered saline; PDGF, platelet-derived growth factor;
TGF-B, transforming growth factor-B.
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